Literature DB >> 19405524

Functionalized congener approach to the design of ligands for G protein-coupled receptors (GPCRs).

Kenneth A Jacobson1.   

Abstract

Functionalized congeners, in which a chemically functionalized chain is incorporated at an insensitive site on a pharmacophore, have been designed from the agonist and antagonist ligands of various G protein-coupled receptors (GPCRs). These chain extensions enable a conjugation strategy for detecting and characterizing GPCR structure and function and pharmacological modulation. The focus in many studies of functionalized congeners has been on two families of GPCRs: those responding to extracellular purines and pyrimidines-i.e., adenosine receptors (ARs) and P2Y nucleotide receptors. Functionalized congeners of small molecule as ligands for other GPCRs and non-G protein coupled receptors have also been designed. For example, among biogenic amine neurotransmitter receptors, muscarinic acetylcholine receptor antagonists and adrenergic receptor ligands have been studied with a functionalized congener approach. Adenosine A(1), A(2A), and A(3) receptor functionalized congeners have yielded macromolecular conjugates, irreversibly binding AR ligands for receptor inactivation and cross-linking, radioactive probes that use prosthetic groups, immobilized ligands for affinity chromatography, and dual-acting ligands that function as binary drugs. Poly(amidoamine) dendrimers have served as nanocarriers for covalently conjugated AR functionalized congeners. Rational methods of ligand design derived from molecular modeling and templates have been included in these studies. Thus, the design of novel ligands, both small molecules and macromolecular conjugates, for studying the chemical and biological properties of GPCRs have been developed with this approach, has provided researchers with a strategy that is more versatile than the classical medicinal chemical approaches.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19405524      PMCID: PMC2888900          DOI: 10.1021/bc9000596

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  128 in total

1.  From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes.

Authors:  P S Portoghese
Journal:  J Med Chem       Date:  2001-07-05       Impact factor: 7.446

2.  Development of a homogeneous high-throughput live-cell G-protein-coupled receptor binding assay.

Authors:  Paul H Lee; Steven C Miller; Carlo van Staden; Evan F Cromwell
Journal:  J Biomol Screen       Date:  2008-05-06

3.  Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin.

Authors:  R A Dixon; B K Kobilka; D J Strader; J L Benovic; H G Dohlman; T Frielle; M A Bolanowski; C D Bennett; E Rands; R E Diehl; R A Mumford; E E Slater; I S Sigal; M G Caron; R J Lefkowitz; C D Strader
Journal:  Nature       Date:  1986 May 1-7       Impact factor: 49.962

4.  Differences in the subcellular localization of alpha1-adrenoceptor subtypes can affect the subtype selectivity of drugs in a study with the fluorescent ligand BODIPY FL-prazosin.

Authors:  Tatsuo Sugawara; Akira Hirasawa; Keitaro Hashimoto; Gozoh Tsujimoto
Journal:  Life Sci       Date:  2002-03-22       Impact factor: 5.037

5.  Purification and characterization of the human adenosine A(2a) receptor functionally expressed in Escherichia coli.

Authors:  H Markus Weiss; Reinhard Grisshammer
Journal:  Eur J Biochem       Date:  2002-01

6.  The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition.

Authors:  Lea Madi; Avivit Ochaion; Lea Rath-Wolfson; Sara Bar-Yehuda; Abigail Erlanger; Gil Ohana; Arie Harish; Ofer Merimski; Faina Barer; Pnina Fishman
Journal:  Clin Cancer Res       Date:  2004-07-01       Impact factor: 12.531

7.  Recent improvements in the development of A(2B) adenosine receptor agonists.

Authors:  Pier Giovanni Baraldi; Mojgan Aghazadeh Tabrizi; Francesca Fruttarolo; Romeo Romagnoli; Delia Preti
Journal:  Purinergic Signal       Date:  2009-01-31       Impact factor: 3.765

Review 8.  Signaling pathways in ischemic preconditioning.

Authors:  James M Downey; Amanda M Davis; Michael V Cohen
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

9.  Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands.

Authors:  Yaguo Zheng; Eyup Akgün; Kaleeckal G Harikumar; Jessika Hopson; Michael D Powers; Mary M Lunzer; Laurence J Miller; Philip S Portoghese
Journal:  J Med Chem       Date:  2009-01-22       Impact factor: 7.446

10.  Electrophilic derivatives of purines as irreversible inhibitors of A1 adenosine receptors.

Authors:  K A Jacobson; S Barone; U Kammula; G L Stiles
Journal:  J Med Chem       Date:  1989-05       Impact factor: 7.446

View more
  28 in total

Review 1.  Xanthines as adenosine receptor antagonists.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2011

2.  Novel Alexa Fluor-488 labeled antagonist of the A(2A) adenosine receptor: Application to a fluorescence polarization-based receptor binding assay.

Authors:  Miklós Kecskés; T Santhosh Kumar; Lena Yoo; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2010-05-11       Impact factor: 5.858

3.  Multivalent dendrimeric and monomeric adenosine agonists attenuate cell death in HL-1 mouse cardiomyocytes expressing the A(3) receptor.

Authors:  Athena M Keene; Ramachandran Balasubramanian; John Lloyd; Asher Shainberg; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2010-03-25       Impact factor: 5.858

4.  Functionalized congeners of A3 adenosine receptor-selective nucleosides containing a bicyclo[3.1.0]hexane ring system.

Authors:  Dilip K Tosh; Moshe Chinn; Andrei A Ivanov; Athena M Klutz; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

Review 5.  The evolving small-molecule fluorescent-conjugate toolbox for Class A GPCRs.

Authors:  Andrea J Vernall; Stephen J Hill; Barrie Kellam
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

6.  Discovery of Quinazoline-Based Fluorescent Probes to α1-Adrenergic Receptors.

Authors:  Wei Zhang; Zhao Ma; Wenhua Li; Geng Li; Laizhong Chen; Zhenzhen Liu; Lupei Du; Minyong Li
Journal:  ACS Med Chem Lett       Date:  2015-03-30       Impact factor: 4.345

7.  Discovery of the First Environment-Sensitive Fluorescent Probe for GPR120 (FFA4) Imaging.

Authors:  Jiaxiang Liu; Chengsen Tian; Tianyu Jiang; Yuqi Gao; Yubin Zhou; Minyong Li; Lupei Du
Journal:  ACS Med Chem Lett       Date:  2017-03-27       Impact factor: 4.345

8.  Nucleoside conjugates of quantum dots for characterization of G protein-coupled receptors: strategies for immobilizing A2A adenosine receptor agonists.

Authors:  Arijit Das; Gangadhar J Sanjayan; Miklós Kecskés; Lena Yoo; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  J Nanobiotechnology       Date:  2010-05-17       Impact factor: 10.435

Review 9.  Structure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates.

Authors:  Kenneth A Jacobson
Journal:  J Med Chem       Date:  2013-05-09       Impact factor: 7.446

10.  Probing GPCR structure: adenosine and P2Y nucleotide receptors.

Authors:  Kenneth A Jacobson; Stefano Costanzi; Francesca Deflorian
Journal:  Methods Enzymol       Date:  2013       Impact factor: 1.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.